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Summary 5'-Deoxy-5-fluorouridine (5'-DFUR) and 1-(tetrahydro-2-furyl)-5-fluorouracil (tegafur), prodrugs of 5-fluorouracil (5-FU), are anti-
cancer agents activated by thymidine phosphorylase (dThdPase). As it is well known that the levels of dThdPase are higher in tumours than
in normal tissue, it should be advantageous to use such pyrimidine antimetabolites for the selective inhibition of tumour growth. However,
tumours are not necessarily sensitive to 5'-DFUR and tegafur because their levels of dThdPase vary. In this study, we examined whether
transfection of tumour cells with a human platelet-derived endothelial cell growth factor (PD-ECGF) complementary DNA (cDNA) expressing
dThdPase would sensitize the cells to the cytotoxic effects of pyrimidine antimetabolites in vitro. A cDNA encoding PD-ECGF was transfected
into PC-9 cells (human lung adenocarcinoma). The transfected cells, PC9-DPE2, had a more than 50 times higher activity of dThdPase than
the parental PC-9 cells or control PC-9 cells transfected with the pcDNA3 vector alone (PC9-Dl). They were more sensitive than parental PC-
9 or PC9-D1 cells not only to 5'-DFUR and tegafur but also to 5-FU. In addition, we demonstrated that PC9-DPE2 cells are able to potentiate
the cytotoxic effects of 5'-DFUR towards co-cultured parental PC-9 cells. This 'bystander effect' did not require cell-cell contact. These results
suggest that transfection of PD-ECGF (dThdPase) genes may be useful as a gene therapy strategy for cancer treatment.
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It is a requirement that chemotherapeutic treatment has cytotoxic
effects on malignant cells only, and not on normal host cells and
tissue. A new strategy in cancer control is the introduction ofa drug
sensitivity gene which encodes an enzyme that can intratumorally
activate a prodrug. One of the representative examples is the herpes
simplex virus thymidine kinase (HSV-TK) gene, which encodes the
protein that activates the nucleoside analogue ganciclovir (GCV)
(Moolten et al, 1990; Freeman etal, 1993a; Oldfield etal, 1993).
dThdPase (EC 2.4.2.4) is an enzyme that catalyses the reversible
phosphorolysis ofthymidine and converts 5'-DFUR and tegafur to
5-FU (Cook et al, 1979; Kramer et al, 1979). Recent studies have
demonstrated that dThdPase is almost identical to PD-ECGF
(Furukawa et al, 1992; Moghaddam and Bicknell, 1992; Usuki et
al, 1992; Sumizawa et al, 1993). It has been also reported that
several types of malignant tumours contain higher levels of this
enzyme than non-malignant tissues (Zimmerman et al, 1964; Fujita
et al, 1983; Kono et al, 1983; Miwa et al, 1987; Yoshimura et al,
1990; Mahmoud et al, 1993). It can be expected that 5-FU
converted from 5'-DFUR and tegafur may inhibit the growth of
cancer cells. However, the chemotherapeutic efficacies of 5'-
DFUR and tegafur against various human tumours are not suffi-
cient as heterogeneity in the levels of dThdPase in the tumours is
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one of the factors relevant to such insufficient chemotherapeutic
indices. As a considerable amount ofdThdPase activity can also be
found in normal tissue, including liver lung, spleen, lymph nodes
and peripheral lymphocytes (Yoshimura et al, 1990), conversion to
5-FU occurs not only in malignant tissue, but also in normal tissue
(Suzuki et al, 1980).
Haraguchi et al (1993) have reported that human KB epidermal
carcinoma cells transfected with a PD-ECGF cDNA expressing
dThdPase (Usuki et al, 1992; Sumizawa et al, 1993) are sensitive
to 5'-DFUR and tegafur. Patterson et al (1995) have investigated
the increased sensitivity to 5'-DFUR in human MCF-7 breast
cancer cells transfected with dThdPase cDNA. Eda et al (1993)
have shown that cytokines induce thymidine phosphorylase in
tumourcells and make them more susceptible to 5'-DFUR in vitro.
In our studies, we investigated whether transfection of tumour
cells with a PD-ECGF cDNA encoding dThdPase would make
them more susceptible to pyrimidine antimetabolites, such as 5'-
DFUR, tegafur and 5-FU. Furthermore, we examined whether 5'-
DFUR and tegafur sensitivity could be transferred to adjacent, low
dThdPase-expressing tumour cells and whether this bystander
effect would require cell-cell contact.
MATERIALS AND METHODS
Chemicals
5'-DFUR was provided by Nippon Roche (Kanagawa, Japan), 5-
FU by Kyowa Hakko (Tokyo, Japan), tegafur by Taiho Pharma-
ceutical (Tokyo, Japan) and cisplatin (CDDP) by Nippon Kayaku
(Tokyo, Japan).
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Cell lines
PC-3 (human lung cancer), PC-9 (human lung cancer), Colo201
(human colon cancer), T-47D (human breast cancer), Lovo
(human colon cancer), SW480 (human colon cancer) and AGS
(human gastric cancer) were used for the following studies.
Transfection of PD-ECGF (dThdPase) cDNA into PC-9
The pPL8 vector containing a full-length PD-ECGF cDNA
(Miyazono et al, 1987; Ishikawa et al, 1989) was kindly provided
by Dr S Akiyama (Institute for Cancer Research, Kagoshima
University, Japan) with permission of Dr K Miyazono (Ludwig
Institute forCancer Research, Uppsala, Sweden). A full-length PD-
ECGF cDNA was obtained by digesting the pPL8 vector with
EcoRl, and ligating the cDNA into the multicloning site of the
mammalian expression vector, pcDNA3 (Invitrogen, San Diego,
USA) (pcDNA3-PD-ECGF). The pcDNA3-PD-ECGF vector was
transformed into competent cells (E. coli, JM109), and the plasmid
DNA was purified using a Flexi-prep kit (Pharmacia, Uppsala,
Sweden). Digestion with BamHI was carried out to identify the
clone that had been ligated with the cDNA in the correct direction.
The pcDNA3-PD-ECGF vector was purified from the E. coli clone
by aQiagen Plasmidkit(Funakoshi,Tokyo,Japan). PC-9 cells were
transfected with the pcDNA3-PD-ECGF or the pcDNA3, as a
control, using LipofectAmine (Gibco BRL, Tokyo, Japan)
according to the instructions ofthe manufacturer. Aftertransfection,
cells were selected for neomycin resistance by treating them with
600 jig ml-1 G418 sulphate (Geneticin; Gibco BRL, Tokyo, Japan).
Ten clones (PC9-DPE) transfected with pcDNA3-PD-ECGF and
ten clones (PC9-D) transfected with pcDNA3 were randomly
selected, and their dThdPase activities and 5'-DFUR sensitivities
were tested. Three clones, PC9-DPE2, -DPE6 and -DPE9, had high
activities ofdThdPase and high sensitivities to 5'-DFUR; dThdPase
activity and sensitivity to 5'-DFUR were similar among these
clones (data not shown). One positive clone, PC9-DPE2, and one
negative clone, PC9-D1, were used for the following studies.
Assay of dThdPase activity
Cultured cells (1 x 107) were homogenized in 100 jl oflysis buffer
consisting of 50 mm Tris-HCl (pH 6.8), 1% Triton X-100, 2 mM
phenylmethylsulphonyl fluoride (PMSF) and 0.02% mercap-
toethanol. These samples were centrifuged at 15 000 r.p.m. for
30 min at 4°C, and 10 jil of the supernatants were used for a
dThdPase activity assay. The protein levels were determined using
the method of Bradford (1976). The enzyme activity was assayed
using the spectrophotometric method described by Yoshimura et al
(1990) and was expressed as nmol thymine mg-' protein h-', using
the molar extinction coefficient (e = 3.8 mm-' cm-') for thymine.
Immunocytostaining and immunoblotting
Anti-human dThdPase monoclonal antibody (mouse IgG1K) was
provided by the Department ofOncology, Nippon Roche Research
Center (Kamakura, Japan). Mouse IgG, as a negative control, was
purchased from Coulter (Florida, USA). The antibody was diluted
to 2 jg ml-1 with goat serum. Immunocytostaining was carried out
using the labelled streptavidin-biotin method (Dako, Kyoto,
Japan), according to the instructions of the manufacturer. The
nuclei were counterstained with haematoxylin.
For immunoblotting, cultured cells were lysed in buffer
containing 50 mm Tris-HCl (pH 8.8), 10% glycerol, 1% sodium
dodecyl sulphate (SDS), 1% 2-mercaptoethanol and 0.0005%
bromophenol blue. The lysates were electrophoresed through 10%
SDS-polyacrylamide gels (20 jig per lane). The gels were trans-
ferred onto a nylon membrane (pore size 0.45 gM; Funakoshi,
Tokyo, Japan). After transfer, the nylon membrane was blocked
with 3% skimmed milk in phosphate-buffered saline (PBS) and
probed with 2 jg ml-1 mouse anti-human dThdPase monoclonal
antibody. The kit described in the immunocytostaining method
was used. Finally, 5 mg of3,3'-diaminobenzidine in 10 ml of PBS
and 3 jl of 30% hydrogen peroxide were used as substrate.
In vitro proliferation rate
Parental PC-9, PC9-D1 and PC9-DPE2 cells were each seeded in
RPMI-1640 (10% fetal calf serum) at 5 x 104 cells into six-well
plates. After 4, 5, 6, 7 and 8 days, cells were released using
trypsin-EDTA andcounted in aCoultercounter (Coulter,FL,USA).
Drug sensitivity test
Approximately 2 x 103 cells were seeded in each well of a 96-well
plate in duplicate and cultured at 37°C in 5% carbon dioxide. After
24 h, anti-cancer agents were added, and the cells were cultured for
5 days. At that stage, the medium was removed, 20 jl of 0.5% 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT;
Sigma chemical, USA) in PBS was administered and the cells were
incubated at 37°C for 4 h. Two hundred microlitres of dimethyl
sulphoxide (DMSO; Wako Pure Chemical Industries Osaka, Japan)
was added to solubilize the MTT formazan, and the absorbance of
each well was measured (Titertek Multiskan MCC/340;Dainippon
Pharmaceutical, Osaka, Japan) at 540 nm (reference absorbance at
630 nm). The effect ofthe drugs on cell survival was expressed as a
growth ratio. The growth ratio was calculated using the following
equation: (AS40 drug-treated/A540 drug-free) x 100. The test was
performed independently six times, and the mean and the s.d. ofthe
IC50 were calculated.
Assessment of bystander effect
PC9-DPE2 and parental PC-9 cells were mixed in various ratios,
i.e. [PC9-DPE2/(parental PC-9 + PC9-DPE2)] = 0, 0.1, 0.2, 0.3,
0.4,0.5,0.6,0.7,0.8,0.9 and 1.0, and were seeded at 2 x 103 cells
per well in 96-well plates. After 24 h, the cells were divided into
two subgroups - one was untreated and the other was treated with
10 jl 5'-DFUR -, and an MTT assay was performed 5 days after
the drug treatment as described above. Data were expressed as
growth ratio (%) relative to drug-free controls.
To examine whether the bystander effect requires direct
cell-cell contact, parental PC-9 cells were plated in the bottom
chamber of24-well culture plates, and PC9-D1 orPC9-DPE2 cells
were placed in the top chamber of the membrane culture inserts
(mixed cellulose ester membrane, pore size 0.45 jim; Iwaki,
Chiba, Japan). The cells were incubated at 37°C in 5% carbon
dioxide, and the test drugs were added into the membrane culture
inserts at various concentrations 24 h later. Five days after drug
treatment, the membrane culture inserts and medium were
removed, 200 jl of 0.5% MTT in PBS was added, and cells were
incubated at 37°C for 4 h. Finally, 1 ml of DMSO was added, and
the absorbance at 540 nm was measured for each well (UV-160A;
British Journal ofCancer (1997) 75(4), 506-511 0 CancerResearch Campaign 1997508 YKato etal
0.03 -
0.02 -
C)
0
.
0.01 -
O-
0 50 100 150
dThdPase Activity (nmol thymine mg-1 protein h-1)
Figure 1 Correlation between dThdPase activity and doxifluridine sensitivity
in human cancer cell lines. Correlation between dThdPase activities and
1/0C50 values for doxifluridine in PC-3 (U), PC-9 (0), AGS (*), SW480 (A),
Lovo (EZ), T47D (0) and Colo201 (A) cell lines was significant (r= 0.92,
P< 0.01)
Table 1 dThdPase activities of parental PC-9, PC9-D1 and PC9-DPE2 cells
dThdPase activity
(nmol thymine mg-' protein h-1)
Parental PC-9 28.7 ± 24.0
PC9-D1 28.0 + 26.7 1 j
PC9-DPE2 1490.7 ± 276.0
dThdPase activity (nmol thymine mg-' protein h-1) was measured
spectrophotometrically. Each value represents the mean ± s.d. of seven
independent experiments. *P< 0.01.
Shimazu, Kyoto, Japan). As control experiments, individual
parental PC-9 or PC9-DPE2 cells were seeded in 24-well plates
without the membrane culture inserts, and cell survival was tested
in the same way as described above.
Statistical analysis
The coefficient of correlation with dThdPase activity and 5'-
DFUR sensitivity of the cell lines was calculated with Pearson's
correlation coefficient, and the significance was tested with
Fisher's calibration.
The differences of the enzyme activity and drug sensitivity
(IC50) were compared using the Student's t-test or Welch's t-test.
C
0.... .~~~~~~~~~~~~~~~~~..... ..
Figure 2 Immunocytostaining of parental PC-9, PC9-D1 and PC9-DPE2
cells. Immunocytostaining was performed using mouse anti-dThdPase
monoclonal antibody as described in 'Materials and methods'. The cytoplasm
of PC9-DPE2 cells (A) was heavily stained, while that of parental PC-9 cells
(B) and PC9-D1 cells (C) was weakly stained
Table 2 Drug sensitivity (IC 0, gIM) of parental PC-9, PC9-D1 and PC9-DPE2 cells
Doxifluridine Tegafur 5-FU Cisplatin
Parental 103.5 ± 42.9 l 59.8 ± 22.7 l 3.17 ± 1.66 l 1.06 +0.27
PC9-D1 94.9 + 43.2 - ] 37.3 ± 16.6 1 2.24 ± 1.01 1 1.31 ± 0.42
PC9-DPE2 0.62 + 0.35 1 2.26 ± 1.04 0.39 ± 0.07 J 1.31 + 0.53 -
IC50 values were determined using the MTT assay. Each value is the mean ±s.d. of six independent experiments. *P< 0.01, **P-value not significant.
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Figure 4 Bystander effect for doxifluridine on PC9-DPE2 cells. Parental PC-
9 and PC9-DPE2 cells were co-cultured in various proportions, and the
sensitivity to 5'-DFUR was examined. Treatment with 10 gM 5'-DFUR showed
a clear bystander effect when the PC9-DPE2 - (parental PC-9 + PC9-DPE2)
ratio was 0.1, and it is more pronounced at a ratio of 0.2 or more (*P< 0.01).
1, Observed growth ratio; 0 predicted growth ratio. Error bars represent the
standard deviation
A
Figure 3 Western blot analysis of dThdPase in parental PC-9, PC9-D1
and PC9-DPE2 cells. Cell lysates were electrophoresed on 10%
SDS-polyacrylamide gels, transferred to nylon membranes and probed with
mouse anti-dThdPase monoclonal antibody as described in 'Materials and
methods'. A 55 kDa protein band was detected in the lysate of PC9-DPE2
cells (lane 1), but not in those of PC9-D1 cells (lane 2) and parental PC-9
cells (lane 3)
Differences were considered to be significant when the proba-
bility (P) value was <0.05.
RESULTS
Correlation between dThdPase activity and 5'-DFUR
sensitivity of human cancer cell lines
We found a significant correlation between dThdPase activity and
sensitivity to 5'-DFUR in various human cancer cell lines,
including PC-3, PC-9, Colo 201, T-47D, Lovo, SW480 and AGS
(r=0.92,P<0.01,Figure 1).
dThdPase activity of parental PC-9, PC9-D1 and PC9-
DPE2 cells
We measured the dThdPase activity ofparental PC-9, PC9-D1 and
PC9-DPE2 cells and confirmed that the dThdPase activity ofPC9-
DPE2 cells was approximately 50 times higher than that of the
others (Table 1).
Characterization of parental PC-9, PC9-D1 and PC9-
DPE2 cells
Parental PC-9, PC9-D1 and PC9-DPE2 cells were immunostained
using anti-human dThdPase monoclonal antibody. The cytoplasm
of the PC9-DPE2 cells was heavily stained while that of the
parental PC-9 and PC9-D1 cells stained weakly (Figure 2).
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Figure 5 Cytotoxic effect of 5'-DFUR (A) and tegafur (B) in non-contact
conditions. The sensitivity to 5'-DFUR and tegafur of parental PC-9 cells that
were co-cultured with PC9-DPE2 cells in non-contact (O) was significantly
higher than that of parental PC-9 cells alone (U) and parental PC-9 cells
which were co-cultured with PC9-D1 cells in non-contact (A)(*P < 0.01). *,
PC9-DPE2 cells alone. Error bars represent the standard deviation
In the immunoblot analysis using a mouse anti-human
dThdPase monoclonal antibody, a 55 kilodalton protein band was
detected in the lysate ofPC9-DPE2 cells, but not in that ofparental
PC-9 and PC9-D1 cells (Figure 3).
In order to examine whether the expression of dThdPase would
influence the cell lines in vitro, the cell doubling times were
assessed. Parental PC-9, PC9-D1 and PC9-DPE2 cells had a
doubling time of40.9, 40.4 and 40.3 h, respectively, with a starting
culture of 5 x 103 cells. The proliferation rate of PC9-DPE2 cells
was very similar to that ofparental PC-9 and PC9-D1 cells.
Drug sensitivity of parental PC-9, PC9-D1 and PC9-
DPE2 cells
The sensitivity of parental PC-9, PC9-D1 and PC9-DPE2 cells to
5'-DFUR, tegafur, 5-FU and CDDP was assessed. PC9-DPE2 cells
were 167, 26 and 8 times more susceptible to 5'-DFUR, tegafur
and 5-FU, respectively, than parental PC-9 cells (P was less than
0.01 for all three drugs). The sensitivity to CDDP among the three
clones was not significantly different. (Table 2).
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Bystander effect
Parental PC-9 and PC9-DPE2 cells were co-cultured in various
proportions, and the sensitivity to 5'-DFUR was examined. During
the treatment with 10 tM 5'-DFUR, there is a clear bystander
effect at a ratio of0.1, and it is more pronounced at 0.2 (Figure 4).
We next examined whether this bystander effect would require
direct cell-cell contact. The sensitivity ofparental PC-9 cells, co-
cultured with PC9-DPE2 cells but not in contact, was significantly
higher than that of parental PC-9 cells alone when 5'-DFUR was
used at 1 ,UM or higher. Sensitivity to tegafur showed a similar
tendency to that of 5'-DFUR, but the drug concentration required
to achieve the bystander effect was ten times higher than that with
5'-DFUR (Figure 5).
DISCUSSION
5'-DFUR and tegafur, prodrugs of 5-FU, are anti-cancer agents
activated by dThdPase (Cook et al, 1979; Kramer et al, 1979;
Haraguchi et al, 1993). It is generally known that human tumours
have higher dThdPase activity than non-neoplastic tissues in the
same organs. Consequently, 5'-DFUR and tegafur may have selec-
tive anti-tumour effects (Zimmerman et al, 1964; Fujita et al,
1983; Kono et al, 1983; Miwa et al, 1987; Yoshimura et al, 1990;
Mahmoud et al, 1993). There is remarkable heterogeneity in the
dThdPase activity of various tumours (Heldin et al, 1993).
Tumours expressing low levels ofdThdPase activity may be insen-
sitive to 5'-DFUR and tegafur. This seems to be compatible with
the present findings indicating a significant correlation between
dThdPase activity and 5'-DFUR sensitivity of various human
cancer cell lines.
We examined whether the sensitivity ofcancercells to 5'-DFUR
and tegafur could be changed by controlling the expression of
dThdPase in vitro. PC9-DPE2 cells, transfected with PD-ECGF
cDNA, had a more than 50 times higher activity ofdThdPase than
parental PC-9 cells or than PC9-D1 cells, transfected with the
pcDNA3 vector alone. The sensitivity of PC9-DPE2 cells to 5'-
DFUR, tegafur and 5-FU was 167, 26 and 8 times higher, respec-
tively, than that ofparental PC-9 cells. Haraguchi et al (1993) have
reported that the sensitivity of KPE-3, KB cells transfected with
PD-ECGF cDNA, to 5'-DFUR and tegafur was significantly
higher than that ofthe untransfected cells. However, the difference
in sensitivity to 5-FU between KPE-3 and KB cells was not signif-
icant. Patterson et al (1995) also demonstrated that the sensitivity
ofMCF-7 cells transfected with dThdPase cDNA to 5-FU was not
higher than that of the untransfected cells. These results are
different to those obtained in this study. The increase ofsensitivity
to 5-FU in PC9-DPE2, however, was marginal. The enzymes that
convert 5-FU to 5-fluorodoxyuridine monophosphate are gener-
ally said to be pyrimidine phosphorybosyl transferase and ribonu-
cleotide reductase. Therefore, we cannot conclude at present
whether the difference in sensitivity to 5-FU would be caused by
enhanced activity ofdThdPase.
In the current study on bystander effect, 10 gM 5'-DFUR
yielded a minor effect with a PC9-DPE2/(parental PC-9 + PC9-
DPE2) ratio of 0.1, and a sufficient effect with a ratio of 0.2 or
more. We found that this bystander effect did not require cell-cell
contact with 5'-DFUR (10 gM) and tegafur (100 gM). As far as we
are aware, this is the first report indicating that a bystander effect
for PD-ECGF/dThdPase-transfected cells does not occur via gap
junctions.
Several investigators have reported a bystander effect in the
HSV-TK-Ganciclovir system which is clinically useful as a gene
therapy. The bystander effect in the HSV-TK - ganciclovir system
has been reported to require cell-cell contact (Freeman et al, 1992,
1993b; Bi et al, 1993). On the other hand, it has been reported that
cancer cells sensitized to cyclophosphamide and ifosfamide by
transfection with the rat P-450 (CYP2B1) cDNA do not require
cell-cell contact for the bystander effect (Wei et al, 1994; Chen et
al, 1995). It appears that ganciclovir metabolites cannot leave the
cell as they are nucleotides, while 5-FU, metabolites of 5'-DFUR
and tegafur and 4-hydroxycyclophosphamide formed by CYP2B1
from cyclophosphamide readily diffuse across cell membranes. As
only homologous cells are joined by gap junctions (Yamasaki,
1991; Pitts, 1994), the contact-type bystander effect may be clini-
cally advantageous because cytotoxic metabolites would transfer
to adjacent cancer cells, but not to the surrounding normal tissue.
However, the contact-type bystander effect may be disadvanta-
geous against cancerous pleuritis and peritonitis, in which cells are
suspended, and against cancer tissue, in which cells are notjoined
by gapjunctions. 5-FU converted by dThdPase can diffuse, even if
gap junctions are down-regulated. Therefore, the bystander effect
of the non-contact type found in this study seems more beneficial
in such cases.
It has been shown that PD-ECGF(dThdPase) stimulates chemo-
taxis of endothelial cells in vitro and has angiogenic activity in
vivo (Ishikawa et al, 1989; Finnis et al, 1993; Fidler et al, 1994;
Miyadera et al, 1995; Moghddam et al, 1995; Toi et al, 1995).
Consequently, it is likely that cells transfected with PD-
ECGF(dThdPase) cDNA may promote surrounding tumour
growth. Therefore, we consider that a transient expression, and not
a stable expression vector, should be used to diminish the risk of
promoting tumour growth by gene transfection.
The usefulness of the PD-ECGF - 5'-DFUR, - tegafur or - 5-
FU system for the enhancement of drug sensitivity and the non-
contact type bystander effect demonstrated in vitro in this study
appear to be promising enough to consider in vivo investigation.
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